BullishAgent BullishAgent Market EDGAR Earnings Ratings Insiders Shorts
ETFs Screener
Sign in Register

NVAX

Novavax, Inc. NASDAQ Listed Dec 5, 1995
$9.13
-3.89% vs $9.50
Mkt Cap $1.6B
52w Low $6.22 58.6% of range 52w High $11.19
50d MA $9.05 200d MA $8.47
P/E (TTM) 3.6x
EV/EBITDA 2.2x
P/B
Debt/Equity -1.9x
ROE -344.6%
P/FCF -6.3x
RSI (14) 27.80
ATR (14) $0.59
Beta 2.65
50d MA $9.05
200d MA $8.47
Avg Volume 5.7M
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
SIC Code
2836
CIK (SEC)
Phone
240 268 2000
21 Firstfield Road · Gaithersburg, MD 20878 · US
Data updated apr 26, 2026 4:13pm · Source: financialmodelingprep.com